DVOŘÁK, Petr, Aleš HAMPL, D. DVOŘÁKOVÁ, M. DOUBEK, J. FAITOVÁ, L. PACHOLÍKOVÁ a J. MAYER. Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia. Leukemia, 2003, roč. 17, č. 12, s. 2418-2425. ISSN 0887-6924.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia
Autoři DVOŘÁK, Petr, Aleš HAMPL, D. DVOŘÁKOVÁ, M. DOUBEK, J. FAITOVÁ, L. PACHOLÍKOVÁ a J. MAYER.
Vydání Leukemia, 2003, 0887-6924.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor Genetika a molekulární biologie
Stát vydavatele Velká Británie
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 5.116
Organizační jednotka Přírodovědecká fakulta
Klíčová slova anglicky cells
Štítky cells
Změnil Změnil: prof. Ing. Petr Dvořák, CSc., učo 47260. Změněno: 1. 2. 2006 13:45.
Anotace
Previously, we showed that expression of myeloma-associated (proto)oncogene fibroblast growth factor receptor 3 (FGFR-3) is increased in white blood cells from patients with chronic myeloid leukemia (CML). The abnormal expression was returned back to the normal levels as soon as these patients reconstituted their hematopoiesis following transplantation of allogeneic peripheral blood stem cells. The aims of this study were: (1) to define population(s) of cells overexpressing FGFR-3, and (2) to determine the expression of FGFR-3 during the clinical course of the disease. We show that the vast majority of FGFR-3 transcripts as well as FGFR-3 protein arise from CD34+ BCR-ABL+ cells. Although increased levels of FGFR-3 were found in majority of late chronic phase patients treated with interferon alpha or hydroxyurea, the expression of FGFR-3 was always lowered following treatment with BCR-ABL tyrosine kinase inhibitor STI571. Compared to unstimulated cells, high levels of FGFR-3 were also identified in CD34+ cells from granulocyte colony-stimulating factor-mobilized blood stem cell harvests from healthy donors, suggesting a potential growth factor-dependent basis for elevated expression of FGFR-3 in CML. These findings have implications for the involvement of FGFR-3 in malignant hematopoiesis and depict FGFR-3 tyrosine kinase in CD34+ leukemic cells as a possible target for tyrosine kinase inhibitors.
VytisknoutZobrazeno: 24. 9. 2020 14:26